Testing Status of AZT + Clarithromycin combination (AIDS Initiative) M960122
CASRN: AZTCLARITHRO
Related: AIDS INITIATIVE
Synonyms/Common Names
- 3'-Azido-3'-deoxythymidine + clarithromycin combination
- Clarithromycin + AZT combination
Secondary:
- 30516-87-1 - 3'-Azido-3'-deoxythymidine (AIDS)
- 30516-87-1 - AZT transplacental carcinogenesis study
- 81103-11-9 - Clarithromycin
Special Studies
- Toxicokinetic Study (Gavage)
(S0646)
Completed
- Male and Female Mice [M]: B6C3F1
- Dose: (gavage) 3 mg/mL clarithro & 3 mg/mL clarithro + 15 mg/mL, AZT (PTKS doses) [M].
Organ Systems Toxicity
- 10 to 30 days Repro/Dev Gen Tox (28-Day) (Gavage)
(RDGT96002)
Completed
- NIH Number: 04-4418
Citation: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Studies of 3'-Azido-3'-deoxythymidine (AZT) and Clarithromycin Combinations (CASRNs 30516-87-1 and 81103-11-9) Administered by Gavage to Swiss (CD-1®) Mice - Male and Female Mice: Swiss CD-1
- Dose: 200 or 400 mg/kg AZT; 500, 1250, or 2500 mg clarithromycin.
- NIH Number: 04-4418
- 10 to 30 days Repro/Dev Gen Tox (28-Day) (Gavage)
(RDGT97001)
Completed
- NIH Number: 04-4418
Citation: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Studies of 3'-Azido-3'-deoxythymidine (AZT) and Clarithromycin Combinations (CASRNs 30516-87-1 and 81103-11-9) Administered by Gavage to Swiss (CD-1®) Mice - Male and Female Mice: Swiss CD-1
- Dose: 200 or 400 mg AZT: 250, 500, or 1000 mg clarithromycin.
- NIH Number: 04-4418